Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 42Neoplasms 6Neoplasm Metastasis 4Colorectal Neoplasms 4Adenocarcinoma 3Resectable Pancreatic Cancer 2Rectal Neoplasms 2Pancreatic Cancer Metastatic 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Urachal cancer 1Stomach Neoplasms 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Neoplasms, Basal Cell 1Locally Advanced Unresectable or Metastatic Solid Tumors 1Localized Pancreatic Adenocarcinoma 1Gastrointestinal Neoplasms 1Gastroesophageal Adenocarcinoma 1Gastro-enteropancreatic neuroendocrine tumor 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Carcinoma 1Borderline Resectable Pancreatic Cancer 1

Interventions

folfirinox 1Taxes 1Oxaliplatin 1Neoadjuvant Therapy 1Leucovorin 1Irinotecan 1Gemcitabine 1FAPI-46 1Endosonography 1Blood Specimen Collection 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pancreatic Ductal Adenocarcinoma (PDAC) × folfirinox × Clear all
NCT02782182 2019-03-19

Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study

University of Chicago

Phase 1 Terminated
1 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma (PDAC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡